ParkinsonCanadaV1, PubMed, Corpus, bibRecord, 001536

Myoclonus in parkinsonian disorders.

Identifieur interne : 001536 ( PubMed/Corpus ); précédent : 001535; suivant : 001537

Myoclonus in parkinsonian disorders.

Auteurs : Mohamed Shafiq ; Anthony E. Lang

Source :

Advances in neurology [ 0091-3952 ] ; 2002.

RBID : pubmed:11968474

English descriptors

KwdEn :
- Antiparkinson Agents (adverse effects), Basal Ganglia, Cerebral Cortex, Humans, Lewy Body Disease (complications), Multiple System Atrophy (complications), Myoclonus (chemically induced), Myoclonus (etiology), Nerve Degeneration (complications), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinsonian Disorders (complications).
MESH :
- chemical , adverse effects : Antiparkinson Agents.
- chemically induced : Myoclonus.
- complications : Lewy Body Disease, Multiple System Atrophy, Nerve Degeneration, Parkinson Disease, Parkinsonian Disorders.
- drug therapy : Parkinson Disease.
- etiology : Myoclonus.
- Basal Ganglia, Cerebral Cortex, Humans.

PubMed: 11968474

Links to Exploration step

pubmed:11968474

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Myoclonus in parkinsonian disorders.</title>
<author><name sortKey="Shafiq, Mohamed" sort="Shafiq, Mohamed" uniqKey="Shafiq M" first="Mohamed" last="Shafiq">Mohamed Shafiq</name>
<affiliation><nlm:affiliation>Department of Medicine (Neurology), Toronto Western Hospital, Toronto, Ontario, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2002">2002</date>
<idno type="RBID">pubmed:11968474</idno>
<idno type="pmid">11968474</idno>
<idno type="wicri:Area/PubMed/Corpus">001536</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001536</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Myoclonus in parkinsonian disorders.</title>
<author><name sortKey="Shafiq, Mohamed" sort="Shafiq, Mohamed" uniqKey="Shafiq M" first="Mohamed" last="Shafiq">Mohamed Shafiq</name>
<affiliation><nlm:affiliation>Department of Medicine (Neurology), Toronto Western Hospital, Toronto, Ontario, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name>
</author>
</analytic>
<series><title level="j">Advances in neurology</title>
<idno type="ISSN">0091-3952</idno>
<imprint><date when="2002" type="published">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term>
<term>Basal Ganglia</term>
<term>Cerebral Cortex</term>
<term>Humans</term>
<term>Lewy Body Disease (complications)</term>
<term>Multiple System Atrophy (complications)</term>
<term>Myoclonus (chemically induced)</term>
<term>Myoclonus (etiology)</term>
<term>Nerve Degeneration (complications)</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinsonian Disorders (complications)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Myoclonus</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Lewy Body Disease</term>
<term>Multiple System Atrophy</term>
<term>Nerve Degeneration</term>
<term>Parkinson Disease</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Myoclonus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Basal Ganglia</term>
<term>Cerebral Cortex</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11968474</PMID>
<DateCreated><Year>2002</Year>
<Month>04</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted><Year>2002</Year>
<Month>10</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised><Year>2005</Year>
<Month>11</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0091-3952</ISSN>
<JournalIssue CitedMedium="Print"><Volume>89</Volume>
<PubDate><Year>2002</Year>
</PubDate>
</JournalIssue>
<Title>Advances in neurology</Title>
<ISOAbbreviation>Adv Neurol</ISOAbbreviation>
</Journal>
<ArticleTitle>Myoclonus in parkinsonian disorders.</ArticleTitle>
<Pagination><MedlinePgn>77-83</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shafiq</LastName>
<ForeName>Mohamed</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Medicine (Neurology), Toronto Western Hospital, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lang</LastName>
<ForeName>Anthony E</ForeName>
<Initials>AE</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Adv Neurol</MedlineTA>
<NlmUniqueID>0367524</NlmUniqueID>
<ISSNLinking>0091-3952</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019578" MajorTopicYN="N">Multiple System Atrophy</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009207" MajorTopicYN="N">Myoclonus</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>42</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year>
<Month>4</Month>
<Day>24</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2002</Year>
<Month>10</Month>
<Day>10</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2002</Year>
<Month>4</Month>
<Day>24</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">11968474</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001536 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001536 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:11968474
   |texte=   Myoclonus in parkinsonian disorders.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:11968474" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Myoclonus in parkinsonian disorders.

Myoclonus in parkinsonian disorders.

Source :

English descriptors

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki